Background The major reasons to treat sarcoidosis are to lower the morbidity and mortality
risk or to improve quality of life (QoL). The indication for treatment varies depending on …

Pulmonary sarcoidosis presents substantial management challenges, with limited evidence
on effective therapies and phenotypes. In the absence of definitive evidence, expert …

The options for treatment of sarcoidosis have expanded. In this article, we outline a stepwise
approach to treatment. Recommendations for treatment are based on available evidence …

Sarcoidosis is a systemic granulomatous inflammatory disease of unknown etiology. It
affects the lungs in over 90% of patients yet extra-pulmonary and multi-organ involvement is …

Sarcoidosis is a multisystem granulomatous disease with large variability in presentation,
disease behavior, and outcome. The cause of sarcoidosis and explanation for its wide …

Introduction: Treatment of sarcoidosis recommendations are often based on clinical
experience and expert opinion. However, there are an increasing number of studies which …

The first international consensus statement on sarcoidosis is currently being copublished in
the journals of the American Thoracic Society (ATS) and the World Association for …

Sarcoidosis is a rare disease with the number of patients in the European Union (28
member states), Norway, Iceland and Lichtenstein estimated as∼ 102 000 [1, 2]. Some 40 …

The focus of this review is current knowledge about the epidemiology, clinical
manifestations, diagnosis, and treatment of both pulmonary sarcoidosis and extrapulmonary …

Background Pulmonary sarcoidosis is a common condition with an unpredictable course.
Oral (OCS) or inhaled steroids (ICS) are widely used in its treatment, but there is no …